FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency - Pfizer pfizer.com Submitted by pfizercom6279 on June 28, 2023 at 11:32 AM in business No comments 54
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus - Pfizer pfizer.com Submitted by pfizercom6279 on June 26, 2023 at 11:58 AM in news No comments 30
Pfizer's TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval - Pfizer pfizer.com Submitted by pfizercom6279 on June 22, 2023 at 1:45 PM in business No comments 35
U.S. FDA Approves Pfizer's VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC) - Pfizer pfizer.com Submitted by pfizercom6279 on October 14, 2023 at 2:09 PM in business No comments 53
Pfizer Completes Acquisition of Seagen - Pfizer pfizer.com Submitted by pfizercom6279 on December 15, 2023 at 12:46 PM in business No comments 43
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer - Pfizer pfizer.com Submitted by pfizercom6279 on December 16, 2023 at 10:07 PM in business No comments 50
Pfizer's LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression - Pfizer pfizer.com Submitted by pfizercom6279 on June 2, 2024 at 8:51 AM in business No comments 62